undamentalytics Newsletter
Sign in

Intellia Therapeutics, Inc. income statement

In fiscal 2025, Intellia Therapeutics, Inc. reported revenue of $67.7m, up 16.9% on the year before, operating income of −$441m (a -651.7% margin) and net income of −$413m, or −$3.81 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1626304358335236586860
Cost of revenue——0000—————
Gross profit——30435833—————
Research and development326889108150230420435466389347
General and administrative17283241447190116126120136
Operating income−32−70−91−106−137−268−458−515−534−441−423
Income before tax−32−68—————————
Income tax0————————0—
Net income−32−68−85−474−134−268−474−481−519−413−400
Diluted EPS−$1.42−$1.88−$1.98−$2.11−$2.40−$3.78−$6.16−$5.42−$5.25−$3.81−$3.35
Diluted shares (average)22m36m43m47m56m71m77m89m99m108m120m
EBITDA−31−67−86−101−130−261−451−506−524−431−414

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FENC vs NTLAIVVD vs NTLACUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Intellia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Intellia Therapeutics, Inc.